文献速递心律失常心力衰竭与心肌病

早发心房颤动与心肌病及心律失常基因罕见变异患病率

Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes.
PubMed 文献 · JAMA Cardiol · 2021-01-01

这项前瞻性观察队列研究纳入1293例66岁前诊断心房颤动的患者,通过全基因组测序检测145个心肌病和心律失常相关基因。结果显示10.1%的患者携带致病/可能致病性变异,30岁前诊断者比例最高(16.8%),且多数变异位于心肌病相关基因。结果支持对早发心房颤动患者进行基因检测。

要点

  • 早发房颤患者中10.1%携带致病/可能致病性变异。
  • 30岁前诊断房颤者该比例达16.8%,60岁后诊断者仅7.1%。
  • 致病/可能致病性变异更多见于遗传性心肌病综合征而非遗传性心律失常。

核心结论

  • 早发房颤患者中约10%携带致病/可能致病性变异,比例在30岁前诊断者更高、60岁后诊断者更低,且多数变异位于心肌病相关基因,支持对早发房颤进行基因检测。

研究设计与样本

  • 前瞻性观察队列研究,纳入1999年11月23日至2015年6月2日期间来自学术医疗中心、66岁前诊断房颤且接受全基因组测序的1293例参与者。

主要发现

  • 1293例参与者中,131例(10.1%)检出致病/可能致病性变异,812例(62.8%)携带意义未明变异,92例(7.1%)为常染色体隐性遗传病杂合携带者,258例(20.0%)未发现可疑变异。
  • 30岁前诊断房颤者检出致病/可能致病性变异的比例为16.8%(20/119,95%CI 10.0%-23.6%),60岁后诊断者为7.1%(8/112,95%CI 2.4%-11.9%)。
  • 致病/可能致病性变异更多与遗传性心肌病综合征相关,常见基因包括TTN(n=38)、MYH7(n=18)、MYH6(n=10)、LMNA(n=9)和KCNQ1(n=8)。

关键数值与推荐

  • 使用美国医学遗传学与基因组学学会标准对罕见变异进行分类:良性、可能良性、意义未明、可能致病、致病。
  • 疾病相关变异定义为常染色体显性或X连锁显性遗传病相关基因中的致病/可能致病性变异。
  • 检测基因为商业临床基因检测实验室所用心肌病和心律失常检测面板中包含的145个基因。

临床怎么用

  • 对66岁前诊断的早发房颤患者,尤其30岁前诊断者,可考虑进行心肌病和心律失常相关基因检测以识别潜在遗传性疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Early-onset atrial fibrillation (AF) can be the initial manifestation of a more serious underlying inherited cardiomyopathy or arrhythmia syndrome. OBJECTIVE: To examine the results of genetic testing for early-onset AF. DESIGN, SETTING, AND PARTICIPANTS: This prospective, observational cohort study enrolled participants from an academic medical center who had AF diagnosed before 66 years of age and underwent whole genome sequencing through the National Heart, Lung, and Blood Institute's Trans-Omics for Precision Medicine program. Participants were enrolled from November 23, 1999, to June 2, 2015. Data analysis was performed from October 24, 2020, to March 11, 2021. EXPOSURES: Rare variants identified in a panel of 145 genes that are included on cardiomyopathy and arrhythmia panels used by commercial clinical genetic testing laboratories. MAIN OUTCOMES AND MEASURES: Sequencing data were analyzed using an automated process followed by manual review by a panel of independent, blinded reviewers. The primary outcome was classification of rare variants using American College of Medical Genetics and Genomics criteria: benign, likely benign, variant of undetermined significance, likely pathogenic, or pathogenic. Disease-associated variants were defined as pathogenic/likely pathogenic variants in genes associated with autosomal dominant or X-linked dominant disorders. RESULTS: Among 1293 participants (934 [72.2%] male; median [interquartile range] age at enrollment, 56 [48-61] years; median [interquartile range] age at AF diagnosis, 50 [41-56] years), genetic testing identified 131 participants (10.1%) with a disease-associated variant, 812 (62.8%) with a variant of undetermined significance, 92 (7.1%) as heterozygous carriers for an autosomal recessive disorder, and 258 (20.0%) with no suspicious variant. The likelihood of a disease-associated variant was highest in participants with AF diagnosed before the age of 30 years (20 of 119 [16.8%; 95% CI, 10.0%-23.6%]) and lowest after the age of 60 years (8 of 112 [7.1%; 95% CI, 2.4%-11.9%]). Disease-associated variants were more often associated with inherited cardiomyopathy syndromes compared with inherited arrhythmias. The most common genes were TTN (n = 38), MYH7 (n = 18), MYH6 (n = 10), LMNA (n = 9), and KCNQ1 (n = 8). CONCLUSIONS AND RELEVANCE: In this cohort study, genetic testing identified a disease-associated variant in 10% of patients with early-onset AF (the percentage was higher if diagnosed before the age of 30 years and lower if diagnosed after the age of 60 years). Most pathogenic/likely pathogenic variants are in genes associated with cardiomyopathy. These results support the use of genetic testing in early-onset AF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Yoneda ZT, Anderson KC, Quintana JA, et al. Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiol. 2021. PMID: 34495297. doi:10.1001/jamacardio.2021.3370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。